{
    "clinical_study": {
        "@rank": "125984", 
        "arm_group": {
            "arm_group_label": "Ketogenic diet", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive the ketogenic diet as a formula delivered via feeding tube.  Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet."
        }, 
        "brief_summary": {
            "textblock": "This research is being done to observe the safety, tolerability, side effects, and\n      effectiveness of the ketogenic diet in people with continuous seizures (status epilepticus)\n      being treated in a neurointensive care unit."
        }, 
        "brief_title": "Ketogenic Diet for Refractory Status Epilepticus", 
        "condition": [
            "Status Epilepticus", 
            "Seizure", 
            "Epilepsy", 
            "Refractory Status Epilepticus", 
            "Medically Resistant Status Epilepticus"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Seizures", 
                "Status Epilepticus"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients 18 years and older in refractory status epilepticus (continuous or recurrent\n             seizures without return to baseline mental status between seizures, lasting > 30\n             minutes) placed on anesthetics/sedating agents (barbiturates or benzodiazepines)\n             after at least one first- and second-line agent failed to control seizures, and with\n             clinical and/or electrographic seizures following attempt to wean anesthetic/sedating\n             agents after 24 hours.\n\n        Exclusion Criteria:\n\n          1. Unstable metabolic condition\n\n          2. Hemodynamic or cardiorespiratory instability\n\n          3. Coagulopathy\n\n          4. Liver failure\n\n          5. Total cholesterol > 300 mg/dL\n\n          6. Inability to tolerate enteral feeds, including ileus\n\n          7. Pregnancy\n\n          8. Family refusal/no consent\n\n          9. Received any propofol infusions within 24 hours\n\n         10. Receiving hemodialysis or plasmapheresis\n\n         11. Known fatty acid oxidation disorder or pyruvate carboxylase deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796574", 
            "org_study_id": "NA_00073063"
        }, 
        "intervention": {
            "arm_group_label": "Ketogenic diet", 
            "description": "4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed", 
            "intervention_name": "Ketogenic diet", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "KetoCal 4:1 liquid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "status epilepticus", 
            "seizure", 
            "epilepsy", 
            "ketogenic diet", 
            "modified Atkins diet"
        ], 
        "lastchanged_date": "February 19, 2013", 
        "link": {
            "description": "Adult Epilepsy Diet Center at Hopkins website", 
            "url": "http://www.hopkinsmedicine.org/neurology_neurosurgery/specialty_areas/epilepsy/adult/adult-epilepsy-diet-center/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "mcerven1@jhmi.edu", 
                    "last_name": "Mackenzie Cervenka"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "investigator": [
                    {
                        "last_name": "Mackenzie C. Cervenka, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Eric H Kossoff, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bobbie Henry, RD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Romer Geocadin, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Arun Venkatasan, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Adam Hartman, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hocker.sara@mayo.edu", 
                    "last_name": "Sara E. Hocker, M.D.", 
                    "phone": "507-774-4741"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Sara E. Hocker, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Feasibility and Tolerability of the Ketogenic Diet in the Treatment of Refractory Status Epilepticus in a Neurointensive Care Unit.", 
        "overall_contact": {
            "email": "mcerven1@jhmi.edu", 
            "last_name": "Mackenzie C. Cervenka, M.D.", 
            "phone": "443-287-0423", 
            "phone_ext": "3"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Mackenzie C. Cervenka, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Whether or not the diet protocol was followed", 
            "measure": "Feasibility", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "reference": [
            {
                "PMID": "22718405", 
                "citation": "Vaccarezza M, Silva W, Maxit C, Agosta G. [Super-refractory status epilepticus: treatment with ketogenic diet in pediatrics]. Rev Neurol. 2012 Jul 1;55(1):20-5. Spanish."
            }, 
            {
                "PMID": "22577217", 
                "citation": "Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012 Aug;135(Pt 8):2314-28. doi: 10.1093/brain/aws091. Epub 2012 May 9. Review. Erratum in: Brain. 2013 Jul;136(Pt 7):2326."
            }, 
            {
                "PMID": "22003821", 
                "citation": "Nam SH, Lee BL, Lee CG, Yu HJ, Joo EY, Lee J, Lee M. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia. 2011 Nov;52(11):e181-4. doi: 10.1111/j.1528-1167.2011.03289.x. Epub 2011 Oct 17."
            }, 
            {
                "PMID": "20813015", 
                "citation": "Nabbout R, Mazzuca M, Hubert P, Peudennier S, Allaire C, Flurin V, Aberastury M, Silva W, Dulac O. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia. 2010 Oct;51(10):2033-7. doi: 10.1111/j.1528-1167.2010.02703.x. Epub 2010 Aug 31."
            }, 
            {
                "PMID": "21523523", 
                "citation": "Cervenka MC, Hartman AL, Venkatesan A, Geocadin RG, Kossoff EH. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. Neurocrit Care. 2011 Dec;15(3):519-24. doi: 10.1007/s12028-011-9546-3."
            }, 
            {
                "PMID": "19845731", 
                "citation": "Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG. The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. Epilepsia. 2010 Jun;51(6):1083-5. doi: 10.1111/j.1528-1167.2009.02388.x. Epub 2009 Oct 20."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796574"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Mackenzie Cervenka", 
            "investigator_title": "Assistant Professor of Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The time (in days) from initiation of the diet to > 50% reduction in frequency and to resolution of electrographic (based on continuous EEG findings) and/or clinical seizures will be recorded.", 
                "measure": "Time to seizure reduction", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed for the duration of the hospital stay, an expected average of 6 weeks"
            }, 
            {
                "description": "Participants will complete a scale ranking convenience, taste, texture, tolerance", 
                "measure": "Ranking of tolerability measures on a 10 point scale", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Reported side effects will be recorded as well as number of patients who develop side effects.", 
                "measure": "Number of participants with adverse events and description of events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "The time (in days) from starting the ketogenic diet to achieving urinary and/or serum ketosis will be recorded.", 
                "measure": "Time to achieving serum and/or urinary ketosis", 
                "safety_issue": "No", 
                "time_frame": "Until serum or urinary ketosis is achieved, an expected average of 2 weeks"
            }
        ], 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}